Thromboxane Receptor Antagonist to Improve Endothelial Cell Function
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study evaluates whether addition of the thromboxane receptor antagonist to chronic
aspirin therapy improves endothelial function and reduces non-platelet thromboxane generation
in patients with established cardiovascular disease. Half of participants will receive
ifetroban and the other half will receive matchcing placebo for the 4 week study period.
Phase:
Phase 2
Details
Lead Sponsor:
Jeffrey Rade
Collaborators:
American Heart Association Cumberland Pharmaceuticals